Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Big drugmakers’ sales all went down in Nov
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Dec 24, 2014 10:35:57
Hanmi racked up the most prescription sales among Korean drugmakers in November, according to Ubist data.

Hanmi’s sales were down 9% to 28.3 billion won, compared to the same month a year ago. Daewoong was No.2 in sales. Its sales also decreased 10.4% to 27.7 billion won.

Chong Kun Dang (CKD), Dong-A ST, CJ Healthcare, Yuhan, and Ildong all experienced sales decreases between 5% and 14% in November.

Industry experts said that pharmaceutical business was lackluster with new stricter marketing rules for the pharmaceutical industry and big drugmakers were clearly affected by the latest regulation changes.

Daewon’s sales jumped 16.4% to 12.8 billion won in November. Its growth rate is the highest among medium to large sized pharmaceutical companies.

Drug maker............Sales.........Growth
Hanmi.....................28.3.........-9.0%
Daewoong...............27.7.......-10.4%
CKD........................25.3........-5.6%
Dong-A ST..............19.6........-13.7%
CJ Healthcare..........15.6 .......-6.0%
Yuhan......................14.3.........-7.1%
Ildong......................13.6.........-6.8%
Daewon...................12.8.........16.4%
Samjin.....................10.8..........4.9%
Ahngook..................10.6.........7.1%
Sales in billion won
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com